Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Omalizumab significantly reduced itch and hives caused by chronic spontaneous urticaria (CSU) as early as Week 1; benefit sustained over 24 weeks of active treatment[1] Omalizumab 300 mg was...
-
New four-year data showed that continued Gilenya treatment reduced brain volume loss by one third when compared to delaying Gilenya by two years. MS patients with higher rates of brain volume...
-
Real-world data showed Gilenya reduced the annualized relapse rate and risk of relapse by around 50% versus interferons or glatiramer acetate Reducing the frequency and probability of future...
-
Secukinumab (AIN457) patients' skin cleared faster and for longer than Enbrel® (etanercept) patients, beginning as early as Week 2[1] Study also showed twice as many secukinumab patients...
-
Data from head-to-head pivotal study showing secukinumab (AIN457) superiority to Enbrel®* (etanercept) in moderate-to-severe plaque psoriasis to be revealed Results from three additional...
-
Pivotal myopic CNV trials with Lucentis® (ranibizumab) show visual acuity improvement of nearly 14 letters with a median of two injections at one year[1] New data suggest early treatment...
-
New four-year data will show continued Gilenya treatment reduced brain volume loss in MS patients compared to delaying treatment with Gilenya by two years Data will strengthen the link between...
-
Im Rahmen der Spendenkampagne "Power of One" kann die Weltöffentlichkeit Dank der neuesten Web- und Mobiltechnologien Malariatests und -medikamente für Kinder in Afrika mitfinanzieren Novartis ist...
-
Power of One permet au public de financer des tests et traitements antipaludéens pour les enfants en Afrique par le biais dernières technologies web et mobiles Novartis est le sponsor «...
-
Power of One enables the public to fund malaria tests and treatments for children in Africa through the latest online and mobile technology Novartis is the exclusive campaign treatment sponsor and...